Aethlon Medical To Merge With North Immunology; AEMD Holders To Retain ~4.75% Of Combined Company, With North Immunology Stockholders To Own ~95.25%; NewCo Expected To Have Pro Forma Equity Value Of ~$346.5M; Oversubscribed $180M Private Placement Expected To Fund NewCo Operations Into H2 2028

Loading news article.

Aethlon Medical To Merge With North Immunology; AEMD Holders To Retain ~4.75% Of Combined Company, With North Immunology Stockholders To Own ~95.25%; NewCo Expected To Have Pro Forma Equity Value Of ~$346.5M; Oversubscribed $180M Private Placement Expected To Fund NewCo Operations Into H2 2028 | WAPE

Aethlon Medical To Merge With North Immunology; AEMD Holders To Retain ~4.75% Of Combined Company, With North Immunology Stockholders To Own ~95.25%; NewCo Expected To Have Pro Forma Equity Value Of ~$346.5M; Oversubscribed $180M Private Placement Expected To Fund NewCo Operations Into H2 2028

Article summary

Related companies

Comments —